
Research Article: New Research | Disorders of the Nervous System

Alpha-synuclein aggregates increase the conductance of substantia nigra dopamine neurons, an effect partly reversed by the KATP channel inhibitor glibenclamide

<https://doi.org/10.1523/ENEURO.0330-20.2020>

Cite as: eNeuro 2020; 10.1523/ENEURO.0330-20.2020

Received: 27 July 2020

Revised: 13 October 2020

Accepted: 18 October 2020

This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data.

Alerts: Sign up at www.eneuro.org/alerts to receive customized email alerts when the fully formatted version of this article is published.

Copyright © 2020 Hill et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

1 Alpha-synuclein aggregates increase the conductance of
2 substantia nigra dopamine neurons, an effect partly reversed
3 by the KATP channel inhibitor glibenclamide.

4 E. Hill¹, R. Gowers^{2,3}, M. J. E. Richardson², M. J. Wall^{1*}

5

6 ¹ School of Life Sciences, Gibbet Hill Campus, University of Warwick, CV4 7AL

7 ² Warwick Mathematics Institute, University of Warwick, CV4 7AL

8 ³ Institute for Theoretical Biology, Department of Biology, Humboldt-Universität zu Berlin,
9 Philippstraße 13, Haus 4, 10115, Berlin, Germany

10

11 * Corresponding author:

12 Dr Mark Wall

13 School of Life Sciences

14 University of Warwick

15 CV4 7AL

16 Mark.wall@warwick.ac.uk

17

18 **Author contributions:** EH and MJW designed the experiments. EH performed the
19 experiments. EH, RG and MJER analysed the data. EH, MJER and MJW wrote the
20 manuscript.

21 **Funding:** EH holds a BBSRC-funded PhD Studentship. RG held an EPSRC funded PhD
22 studentship.

23 **Conflicts of Interest:** The authors declare that there are no competing or conflicting
24 interests

25

26 **Abstract**

27 Dopaminergic neurons in the substantia nigra pars compacta (SNpc) form an important part
28 of the basal ganglia circuitry, playing key roles in movement initiation and co-ordination. A
29 hallmark of Parkinson's disease (PD) is the degeneration of these SNpc dopaminergic
30 neurons leading to akinesia, bradykinesia and tremor. There is gathering evidence that
31 oligomeric alpha synuclein (α -syn) is one of the major pathological species in PD, with its
32 deposition in Lewy bodies closely correlated with disease progression. However the precise
33 mechanisms underlying the effects of oligomeric α -syn on dopaminergic neuron function
34 have yet to be fully defined. Here we have combined electrophysiological recording and
35 detailed analysis to characterise the time-dependent effects of α -syn aggregates (consisting
36 of oligomers and possibly small fibrils) on the properties of SNpc dopaminergic neurons. The
37 introduction of α -syn aggregates into single dopaminergic neurons via the patch electrode
38 significantly reduced both the input resistance and the firing rate without changing the
39 membrane potential. These effects occurred after 8-16 minutes of dialysis but did not occur
40 with the monomeric form of α -syn. The effects of α -syn aggregates could be significantly
41 reduced by pre-incubation with the ATP-sensitive potassium channel (KATP) inhibitor
42 glibenclamide. This data suggests that accumulation of α -syn aggregates in dopaminergic
43 neurons may chronically activate KATP channels leading to a significant loss of excitability
44 and dopamine release.

45

46

47 **Significance statement**

48 Alpha synuclein oligomers are one of the key toxic species in Parkinson's disease, with their
49 accumulation leading to dopamine neuron dysfunction. Introducing alpha synuclein

50 aggregates (oligomers and possibly small fibrils) into single substantia nigra dopamine
51 neurons led to a marked increase in whole cell conductance and a corresponding fall in the
52 firing rate. These changes were diminished by inhibiting ATP-sensitive K channels. Thus, the
53 build-up of alpha synuclein oligomers during the progression of Parkinson's disease could
54 chronically shunt dopamine neurons, via channel activation (which may include KATP
55 channel activation) to reduce dopamine release.

56 **Introduction**

57 Mid-brain dopaminergic neurons (DNs) play major roles in the control of movement, emotion,
58 arousal and reward behaviour. They possess large numbers of projections, have pacemaker
59 activity (firing action potentials at rest) and are therefore highly energy intensive. This makes
60 them particularly sensitive to oxidative damage (which can lead to mitochondrial dysfunction,
61 Michel et al, 2016) and they are the most susceptible to degeneration in Parkinson's disease
62 (PD, Damier et al, 1999). DN's are lost over the progression of PD, primarily from the
63 substantia nigra pars compacta (SNpc) but later in the disease there is also loss from the
64 ventral tegmental area (VTA). Symptoms of PD only become apparent when 70-80 % of the
65 dopamine input to the striatum is lost (Bernheimer et al, 1973) making it difficult to detect PD
66 at early stages. Understanding what happens to these dopaminergic neurons early in
67 pathology is important as it could provide improved diagnosis and potentially new targets to
68 prevent or slow disease progression.

69 Alpha synuclein (α -syn) is a small, native intracellular protein, found primarily at presynaptic
70 terminals (Iwai et al, 1995) where it contributes to neurotransmitter uptake and vesicle
71 recycling. It can also localise to the mitochondria and the nucleus (Burre et al, 2010).
72 Molecules of α -syn are intrinsically disordered (Alderson and Markley, 2013) but can
73 become ordered upon aggregation, triggering a pathological cascade. First α -syn
74 aggregates into soluble oligomers (dimers and trimers) and then it can go on to form longer
75 fibrils and ultimately it can form insoluble Lewy Bodies (LB; Spillantini et al, 1997). Lewy

76 bodies are a key pathological marker in the brains of PD patients with their abundance
77 correlating with disease severity. LB formation involves a complex interplay between α -syn
78 fibrillization, post-translational modifications, and interactions of α -syn aggregates with
79 membranous organelles. LB formation can lead to the disruption of mitochondrial function, to
80 synapse dysfunction and of a decline in general cell function (Mahul-Mellier et al. 2020).
81 However, there is also evidence that the small soluble oligomers contribute to toxicity
82 (Winner et al, 2011; reviewed in Bengoa-Vergniory et al, 2017). At the presynaptic terminal,
83 oligomeric α -syn can induce synaptic dysfunction by disrupting vesicle trafficking (Jakes et
84 al, 1994). It also interferes with synaptobrevin in the SNARE complex which is vital for the
85 fusion of vesicles with the plasma membrane for neurotransmitter release (Burre et al, 2010;
86 Murphy et al, 2000; Lashuel et al, 2013). Kaufmann et al (2016) showed that α -syn
87 oligomers reduced the excitability and input resistance of cortical pyramidal cells.

88 In this study, we have used whole-cell patch-clamp recording to provide a detailed
89 characterisation of the electrophysiological effects of introducing aggregated α -syn
90 (oligomers plus a small proportion of fibrils) into single dopaminergic neurons in the
91 substantia nigra of mouse brain slices. Since the α -syn aggregates are only introduced into
92 one neuron, there will be no compensation within the circuit and any slow cellular uptake
93 steps (which may occur if α -syn aggregates were applied extracellularly) are removed. Each
94 cell acts as its own internal control, as at the time of whole-cell breakthrough the α -syn
95 aggregates will not have diffused into the neuron This approach has successfully been used
96 to examine the effects of oligomeric tau on pyramidal neurons (Hill et al, 2019) and the
97 effects of α -syn oligomers on layer-V pyramidal cells in the neocortex (Kaufmann et al,
98 2016).

99 As well as using standard-IV relationships (with step-current injections) to measure the
100 changes in dopaminergic neuron electrophysiology, we have also utilised the dynamic-IV
101 protocol. This was originally applied with cortical pyramidal neurons and interneurons (Badel

102 et al, 2008a; Badel et al, 2008b; Harrison et al, 2015) and can be used to develop simplified,
103 but empirically verified quantitative models of their responses. Though the cortical cells in
104 the original study exhibit non-linear voltage and calcium-activated currents, under ongoing
105 *in-vivo*-like fluctuating current stimulation their response could be well captured by an
106 effective linear I-V curve (away from action potential threshold). Dopaminergic neurons,
107 however, have more strongly expressed non-linearities (Richards et al, 1997; Neuhoff et al
108 2002), and it can therefore be anticipated that the resulting dynamic-IV curves will diverge
109 from an Ohmic linear form below threshold. Despite this, we have determined that the
110 dynamic IV can still be used to accurately extract a number of key electrophysiological
111 parameters.

112 Using these approaches, we have characterised the real-time effects of α -syn aggregates on
113 the electrophysiological properties of single neurons. We find that their major effect is to
114 induce an increase in whole-cell conductance, which significantly dampens neuronal
115 excitability and firing rate. These effects were partially but significantly reduced by
116 glibenclamide, an ATP-sensitive K channel inhibitor, suggesting a role for these channels in
117 the pathological actions of α -syn aggregates.

118 **Methods**

119 ***Preparation of acute brain slices***

120 All experiments were approved by the local Animals Welfare and Ethics Board (AWERB) at
121 the University of Warwick. C57/Bl6 mice (2-3 weeks; of either sex) were killed by cervical
122 dislocation and decapitated in accordance with the U.K. Animals (Scientific Procedures) Act
123 (1986). The brain was rapidly dissected and kept on ice. The cerebellum was removed, and
124 the rostral section of the brain was trimmed. The brain was then mounted rostral side down.
125 Coronal slices (350 μ M) were cut with a Microm HM 650V microslicer in cold (2-4°C) high
126 Mg^{2+} , low Ca^{2+} aCSF, composed of (mM): 127 NaCl, 1.9 KCl, 8 $MgCl_2$, 0.5 $CaCl_2$, 1.2
127 KH_2PO_4 , 26 $NaHCO_3$, 10 D-glucose (pH 7.4 when bubbled with 95% O_2 and 5% CO_2 , 300

128 mOSM). Slices were stored at 34 °C in standard aCSF (1 mM Mg²⁺ and 2 mM Ca²⁺) for at
129 least 1 hour before recording and were viable for up to 8 hours.

130 ***Preparation of alpha synuclein aggregates***

131 Recombinant human alpha-synuclein protein aggregates were purchased from Abcam
132 (ab218819). These aggregates are advertised as pre-formed fibrils (PFFs) which was
133 confirmed using negative-stain electron microscopy. Since we wanted to introduce smaller
134 oligomeric species of alpha synuclein into neurons, the PFFs were first broken down into
135 smaller aggregates before recordings were made. PFF samples were sonicated (as in
136 Polinski et al, 2018) for 15 minutes (50-60 Hz) at room temperature using a Grant Ultrasonic
137 XUBA1 bath. . Recombinant human alpha-synuclein protein in monomeric form (ab218818)
138 was used as a control and negative-stain electron microscopy was used to confirm it was not
139 aggregated.

140 ***Transmission electron microscopy***

141 Formvar/carbon-coated 300-mesh copper grids (#S162, Agar Scientific) were glow-
142 discharged using the ELMO system from Cordouan Technologies. Five microliters of alpha
143 synuclein species (monomer, PFF or sonicated PFFs) were pipetted onto the grid and
144 allowed to bind for 1 min. Excess samples were removed with a strip of filter paper, and 5 µl
145 of 2% uranyl acetate added for 1 min. After removing the excess stain with a strip of filter
146 paper, the grids were imaged using a JEOL-2100F transmission electron microscope.

147 ***Whole-cell patch-clamp recording***

148 A slice was transferred to the recording chamber, submerged and perfused (2-3 ml/min⁻¹)
149 with aCSF at 30-32 °C. Slices were visualized using IR-DIC optics with an Olympus
150 BX151W microscope (Scientifica, Bedford UK) and a CCD camera (Hitachi). Whole-cell
151 current-clamp recordings were made from dopaminergic neurons in the substantia nigra pars
152 compacta using patch pipettes (5–10 MΩ) manufactured from thick-walled glass (Harvard
153 Apparatus, Edenbridge, UK). Intracellular solution was filtered before use (0.2 µm) and

154 contained in (mM): potassium gluconate 135, NaCl 7, HEPES 10, EGTA 0.5,
155 phosphocreatine 10, MgATP 2, NaGTP 0.3, 293 mOSM, pH 7.2). The intracellular solution
156 was filtered (2-4 μm) before the addition of α -syn aggregates (2 μl of a 69 μM stock into 275
157 μl intracellular solution to give final concentration of 500 nM) as filtering reduces the
158 aggregate concentration (Hill et al, 2020; Kaufmann et al, 2016). The molar concentrations
159 of alpha-synuclein species are based on the molar mass of monomeric alpha-synuclein (14
160 kD) due to the likelihood that samples will contain a range of aggregate sizes. This method
161 has been used in similar studies (see Hill et al, 2019 and Thakur et al, 2019) and will result
162 in an overestimate of aggregate concentration. For example if aggregates are on average
163 tetramers, then the concentration of aggregates will be 4x lower than reported. A subset of
164 neurons were filled with AF594 dye (50 μM) via the patch pipette for immunohistochemistry.
165 Voltage recordings were made using an Axon Multiclamp 700B amplifier (Molecular Devices,
166 USA) and digitised at 20 KHz. Data acquisition and analysis were performed using pClamp
167 10 (Molecular Devices). Recordings from neurons that had a resting membrane potential of
168 between -55 and -75 mV at whole-cell breakthrough were accepted for analysis. The bridge
169 balance was monitored throughout the experiments and any recordings where it changed by
170 more than 20 % were discarded.

171

172 ***Stimulation Protocols***

173 *Standard IV protocol:* Standard current-voltage relationships (SIV) were constructed by
174 injecting step currents (3 s duration, with a 5 s interval) starting at -200 pA and then
175 incrementing by either 50 or 100 pA until a regular firing pattern was induced.

176 *Naturalistic current injection:* A naturalistic, fluctuating current (40 s duration, see below for
177 details) was injected into neurons and the resulting voltage trace was used to measure the
178 frequency of action-potential firing (using threshold detection in Clampfit).

179

180 ***Immunohistochemistry***

181 After completing the electrophysiology recordings from dopaminergic neurons, with the
182 addition of AF594 dye (50 μ M) in the patch pipette, slices (350 μ M) were fixed in 4% PFA for
183 45 minutes at room temperature and then overnight at 4°C. The tissue was then washed 5
184 times for 5 minutes with PBS. The slices were then blocked for an hour (1% BSA, 0.4%
185 Triton 100X in PBS, 400 μ l per slice) then washed 3 times for 5 minutes with PBS. The
186 primary antibodies against tyrosine hydroxylase (1:1000, Sheep), was added to the slices
187 (250 μ l per slice) for an hour at room temperature and then kept at 4-8°C overnight. Slices
188 were washed 5 times for 5 minutes with PBS and then the secondary antibody was added
189 (anti-sheep 488, 1:500, 200 μ l per slice) for 4 hours at room temperature. The slices were
190 then washed 5 times for 5 minutes with PBS, and then mounted on glass slides with
191 Vectashield (Vector laboratories, Peterborough UK). All imaging was carried using confocal
192 microscopy (Leica 710 and Zen Black for image acquisition and processing). Controls were
193 carried out without incubating with the primary antibodies and showed no fluorescence.

194 ***Drugs and substances***

195 Recombinant human alpha-synuclein aggregates were purchased from Abcam (ab218819)
196 along with the corresponding monomers (ab218818). Dopamine (HB1835) and ZD 7288
197 (HB1152) were purchased from Hello Bio (HB1835). Glibenclamide (PHR1287) was
198 purchased from Sigma-Aldrich. The Sheep polyclonal Anti-Tyrosine hydroxylase was
199 purchased from Merck (AB1542) and Donkey anti-sheep 488 secondary from Invitrogen
200 (A11015). The Alexa Fluor 594 hydrazide dye was purchased from Molecular Probes
201 (10072752).

202

203

204 ***Statistics***

205 Each recorded cell is one data point. All experimental conditions were measured using
206 multiple animals as only 1 cell was recorded per slice and recording conditions were
207 interleaved to remove bias introduced from individual animals. Data points for each
208 experimental condition were derived from a minimum of 4 individual animals (the exact
209 numbers are provided in the figure legends). Statistical analysis was performed using non
210 parametric methods: Kruskal–Wallis one-way analysis of variance (ANOVAs), Mann Whitney
211 and Wilcoxon signed-rank tests as required. All data is represented as mean and standard
212 error of the mean with individual experiments represented by single data points. Standard
213 deviations are given in table 1.

214

215 ***Neuronal parameter extraction***

216 Both the standard IV-curve (response to constant current inputs) and dynamic IV-curve
217 (Badel et al, 2008) methods were used to extract estimates for the cellular conductance
218 under the various pharmacological conditions. The voltage was modelled by the following
219 the current-balance equation

$$220 \quad C \frac{dV}{dt} + I_{ion} = I_{inj} \quad \text{Eq 1}$$

221 where C is the capacitance, I_{ion} is the summed intrinsic current (including voltage-gated and
222 calcium-gated currents) and I_{inj} is the current injected via the electrode during the different
223 protocols. All computational modelling and data-fitting was carried out using custom written
224 code in the Julia language (Bezanson et al, 2014) ported from published MATLAB code
225 (Harrison et al, 2015).

226 ***Standard IV curve***

227 To calculate neuronal resistance, the maximum voltage deflection to the -100 pA current
228 step (before the sag, arrow on Fig 2A) was measured (peak neuronal resistance). The
229 position for the voltage measurement was determined on the voltage traces at time zero

230 (where there was a clear peak), and then the same position was used for the rest of the
231 voltage traces at subsequent time points.

232 *Dynamic IV curve*

233 As well as measuring the static properties of the neuron at rest it is also useful to measure
234 the effective parameters when the neuronal voltage is subject to a fluctuating drive, as is the
235 case in-vivo. To this end we employed the dynamic IV-curve protocol (Badel et al, 2008) in
236 which a stochastic current I_{inj} is injected into the cell to induce a fluctuating voltage response
237 and triggering of action potentials (Fig 2B). A detailed description of the protocol has been
238 previously published (Badel et al, 2008) as well as the computer code required (Harrison et
239 al, 2015). In brief, a noisy current trace I_{inj} is generated computationally (from the sum of two
240 Ornstein-Uhlenbeck gaussian processes with time constants $\tau_{fast} = 3$ ms and $\tau_{slow} = 10$ ms to
241 mimic AMPA and GABA_A receptor time courses) and injected into the cell with the resultant
242 voltage measured. The voltage equation 1 can be re-arranged for the ionic current to give

$$243 \quad I_{ion} = I_{inj} - C \frac{dV}{dt} \quad \text{Eq 3}$$

244 where the injected current is known, and the derivative can be calculated from measured
245 voltage (with the capacitance extracted using the method in Badel et al, 2008). The ionic
246 current and voltage time courses can then be plotted against each other (see Fig. 2C, red
247 scattered points). Given the interaction of the gated ionic currents with the stochastic
248 injected current, there is significant scatter in the relation. However, the ionic current can be
249 averaged in voltage slices to provide the dynamic IV-curve (see Fig 2C, black solid line and
250 expanded view in Fig 2D). Once the dynamic IV-curve has been obtained the various
251 features can be extracted such as the ohmic conductance - the linear component of the IV-
252 curve at more hyperpolarised subthreshold voltage - and the excess depolarisation-activated
253 current seen in these cells near threshold.

254

255 By using both DIV and SIV we use two independent methods that induce distinct voltage
256 dynamics to extract neuronal parameters thereby increasing the robustness of the data.
257 These approaches also examine the neurons under different conditions. For SIV, the
258 parameters are extracted from neurons that are in a simple dynamical state. In contrast the
259 fluctuations induced by the DIV protocol result in a voltage that rapidly explores a much
260 larger range.

261

262

263 **Results**

264 **Characterising dopaminergic neurons in the substantia nigra**

265 Whole-cell patch-clamp recordings were made from putative dopaminergic neurons located
266 in the SNpc (identified by position in the slice). Neurons were initially confirmed to be SNpc
267 dopaminergic neurons from their electrophysiological profile, which was consistent with
268 previous studies (Grace and Onn, 1989; Richards et al 1997; Krashia et al 2017). Most of
269 the recorded neurons displayed slow autonomous firing (36 out of 49 neurons, 73 %, mean
270 firing rate of 1.05 ± 0.082 Hz Fig 1A) consistent with the reported properties for dopamine
271 neurons in the SNpc (Grace and Onn, 1989). These neurons were sensitive to dopamine
272 (Lacey et al 1989), with application of dopamine ($30 \mu\text{M}$) hyperpolarising the membrane
273 potential by 7.35 ± 1.24 mV and abolishing the spontaneous firing (Fig 1A, $n = 8$). The
274 neurons showed a characteristic (Neuhoff et al, 2002) response to step-current injection (Fig
275 1B), with a large sag in response to hyperpolarising current steps (Fig 1C) indicative of the
276 presence of I(h). Following the termination of hyperpolarising-current steps there was a
277 rebound potential leading to firing in 33 out of 49 neurons (68 %, Fig 1C) another
278 characteristic of I(h). Dopamine reduced the firing in response to the positive current steps
279 and to the naturalistic current injection (firing rate reduced to 62.7 ± 0.2 % of that in control).
280 Dopamine also reduced the voltage response to hyperpolarising current steps (indicative of

281 an increase in whole-cell conductance) and also abolished the rebound firing (Fig 1D).
282 Application of ZD7288 (100 μ M), a pharmacological inhibitor of I(h) in dopamine neurons
283 (Harris and Constanti, 1995) greatly reduced the sag response produced by hyperpolarising
284 current steps and also abolished the rebound firing, confirming that they were I(h) mediated
285 (Fig 1E, $n = 6$). Finally, to confirm that the neurons were dopaminergic, a subset of the
286 recorded neurons ($n = 9$) were filled with AF594 dye via the patch pipette and
287 immunofluorescence staining was used to confirm that they were tyrosine hydroxylase
288 positive (Fig 1F).

289 **Detailed analysis of the electrophysiology of dopaminergic neurons in the** 290 **substantia nigra**

291 We used two approaches to characterise changes that occurred when SNpc dopaminergic
292 neurons had either α -syn aggregates, monomers or vehicle introduced. The first constituted
293 of measurements from standard IV-curve protocols during which neurons received constant-
294 current (step) inputs (Fig. 2A). The second approach measures neuronal properties using
295 the dynamic IV-curve protocol (Badel et al, 2008a, 2008b; Harrison et al, 2015) during which
296 neurons were stimulated by a stochastic current mimicking fluctuating synaptic drive (Fig 2B-
297 D). This methodology allows for the average ionic current at a particular voltage to be
298 measured at a good resolution over the full voltage range. The resulting dynamic IV-curve
299 can be used to provide capacitance, ohmic conductance at hyperpolarised regimes as well
300 as the strength of excess current seen near threshold in these cells (see Fig. 2B-D). It is
301 clear that the dynamic IV curve diverges from linear at potentials above ~ -50 mV (but below
302 action-potential threshold) which is characteristic of a depolarisation-activated outward
303 current (Fig 2D). This effect of the outward current can be isolated by subtracting an
304 extrapolated fit to the linear portion of the dynamic IV curve (as illustrated in the inset to Fig
305 2D).

306 **Characterising the structure of the alpha synuclein (α -syn) aggregates**

307 Recombinant human alpha-synuclein protein was purchased from Abcam in the form of pre-
308 formed fibril aggregates (PFFs; ab218819) and in the form of monomers (ab218818).
309 Negative stain- transmission electron microscopy (TEM) was initially to confirm that the
310 samples were either monomeric (Fig 3B) or PFFs (Fig 3C). To enable delivery of
311 aggregates, mostly in oligomeric form, via the patch pipette, the PFFs were broken down.
312 We used sonication (as in Polinski et al, 2018) for 15 minutes (50-60 Hz). We compared the
313 structure of the α -syn aggregates (sonicated PFFs) to oligomeric tau which had an annular
314 structure (Fig 3A, Hill et al 2019) to ensure that it consisted of oligomeric species (Fig 3B).
315 These oligomeric forms were stable for at least 3 hours on ice. While the majority of the
316 species in our samples had an oligomeric structure, we cannot exclude the possibility that
317 other forms of aggregates exist (for example small ~50 nm fibrils; Polinski et al, 2018). We
318 therefore use the term aggregates rather than oligomers. Monomeric or aggregated α -syn
319 samples were introduced into dopaminergic neurons via the patch pipette.

320 **Alpha-synuclein aggregates but not monomers have marked effects on the**
321 **electrophysiological properties of SN dopaminergic neurons.**

322 We introduced either aggregated or monomeric alpha synuclein (500 nM, same
323 concentration as Kaufman et al, 2016) via the patch pipette during whole-cell current-clamp
324 recording from identified SNpc DNs. To ensure consistency, all molar concentrations were
325 based on the molar mass of monomeric alpha-synuclein as the samples probably contain a
326 range of aggregate sizes (see above). Electrophysiological parameters were then measured
327 from the voltage responses to step currents (standard IV, SIV) and naturalistic current
328 injections (dynamic IV, DIV). The currents for SIV and DIV were injected at 8-minute
329 intervals for the duration of recordings (32 minutes; Kaufmann et al, 2016). In control
330 experiments, the same volume of vehicle (2 μ l PBS) was added to the intracellular solution.
331 Recordings (α -syn aggregates, monomers or vehicle) were made from SNpc dopaminergic
332 neurons in interleaved slices to minimise variation.

333 At time zero (a few minutes following whole-cell breakthrough) there was no significant
334 difference in the measured parameters from SIVs (membrane potential $P = 0.4657$,
335 resistance $P = 0.2747$ and firing rate $P = 0.8511$, Table 1) between neurons which had
336 received either vehicle, α -syn monomers or aggregates. Thus, the recording quality and
337 neuronal properties were comparable between the experimental groups. However, as
338 illustrated in the example in Fig 4A, there were marked changes in the SIV during recording
339 from neurons in which α -syn aggregates had been introduced. The changes in SIV,
340 reduction in voltage responses and decrease in firing rate at positive potentials, were
341 indicative of a significant fall in neuronal resistance and the opening of a membrane channel.
342 Such large changes in the SIV did not occur in the neurons that received either α -syn
343 monomers or vehicle (Fig 4B, C). For the neurons injected with α -syn aggregates, after 32
344 minutes of recording, the resistance was significantly ($p = 0.0029$, $n = 11$) reduced to $63 \pm$
345 9.21 % of the resistance measured at 0 mins (Fig 4D). There was no significant changes in
346 the resistance for neurons injected with either α -syn monomers ($P = 0.4688$, $n = 6$) or
347 vehicle ($P = 0.0645$, $n = 10$) over the duration of recordings (at 32 mins IR was $94 \pm 5\%$ of
348 the resistance measured at time 0 mins for vehicle and 99 ± 9 % of resistance measured at
349 time 0 mins for monomers, Fig 4D). At the 32-minute time point there was a significant ($P =$
350 0.0007) difference in resistance between the neurons that received α -syn monomers or
351 vehicle to those where α -syn aggregates were introduced. We investigated the time at which
352 α -syn aggregates began to affect neuronal resistance and found that the difference in
353 resistance between control and aggregated and monomeric α -syn neurons first became
354 significant at the 16 minute time point ($p = 0.0048$; Figure 4D). Thus, the resistance started
355 to fall (presumably as membrane channels opened) between 8 to 16 minutes after α -syn
356 aggregate introduction into the neuron at whole-cell break through.

357 The recorded neurons had a membrane potential of around -55 mV (see Table 1
358 supplementary data) at the start of recordings. For all experimental conditions, the
359 membrane potential slowly and weakly depolarised over the duration of the recordings (Fig

360 4E). For vehicle, the mean depolarisation (ΔV_m) was 6.2 ± 1.82 mV after 32 minutes of
361 recording ($P = 0.0234$, $n = 10$), for α -syn monomers ΔV_m was 3.8 ± 1.2 mV ($P = 0.0938$, $n =$
362 6) and for α -syn aggregates ΔV_m was 6.8 ± 1.85 mV ($P = 0.0107$, $n = 11$). There was no
363 statistically significant difference between the membrane potentials of the control (vehicle
364 and monomers) vs α -syn aggregates across the duration of the recordings ($P = 0.3273$).
365 Thus although α -syn aggregates markedly reduced neuronal resistance they did not produce
366 a significant change in the membrane potential.

367 For control neurons (vehicle), although the membrane potential was depolarised, the change
368 in firing rate did not reach significance ($P = 0.1895$, measured from the naturalistic current
369 injection, firing rate at 32 mins was 124.7 ± 1.3 % of the firing rate at time 0 mins, $n = 10$, Fig
370 4F, G). For neurons which received α -syn monomers, although the membrane potential was
371 depolarised there was also no significant ($P > 0.9999$) change in the firing rate (measured
372 from the naturalistic current injection, firing rate at 32 mins was 120.4 ± 2.4 % of the firing
373 rate at time 0 mins, $n = 6$, Fig 4F, G). For the neurons which had α -syn aggregates
374 introduced, there was a significant ($P = 0.0020$) reduction in the firing rate (at 32 mins the
375 firing rate was 42.3 ± 9.3 % of the firing rate measured at 0 mins, $n = 11$, Fig 4F, G). When
376 comparing control (vehicle and monomers) vs α -syn aggregates there was a significant
377 difference in the firing rate at 32 minutes ($P = 0.0061$). This fall in firing rate induced by α -
378 syn aggregates is consistent with the marked fall in neuronal resistance.

379 Alpha-synuclein aggregates decreased the occurrence of rebound firing following the
380 termination of hyperpolarisation steps (73 % of neurons (8/11) showed rebound firing at 0
381 mins, but only 18 % (2/11) still showed it after 32 minutes of recording). In contrast, all the
382 control neurons that initially displayed rebound firing (60 %, (6/10)) still showed it after 32
383 minutes of recording. Aggregated α -syn also reduced the occurrence of tonic firing (64 % of
384 neurons (7/11) were initially spontaneously active but after 32 minutes only 27 % (3/11) of
385 neurons were still active). For control neurons, 80 % (8/10) initially displayed tonic firing,

386 with 60 % (6/10) still active after 32 minutes of recording. We examined at what time the
387 neurons stopped spontaneously firing and found that on average control (vehicle) neurons
388 that ceased firing stopped firing at 26 ± 3.7 minutes, which was similar to the time for
389 neurons that received α -syn monomers (28 ± 3.64 minutes). The neurons that received α -
390 syn aggregates stopped firing significantly earlier (15.1 ± 2.33 minutes) than either control
391 (vehicle) neurons ($P = 0.0274$) or neurons that received α -syn monomers ($P = 0.0392$).

392

393

394 **Further analysis of the effects of α -syn aggregates on dopaminergic neurons using**
395 **the dynamic IV curve**

396 In control neurons (vehicle) the DIV curve did not markedly change throughout the duration
397 of recordings (Fig 5A). In contrast α -syn aggregates induced significant changes to the DIV,
398 in particular increasing the slope (Fig 5B). These effects were not observed with α -syn
399 monomers (Fig 5C). For all experimental conditions, there were no significant changes in the
400 cellular capacitance ($P = 0.18$, Fig 5E). Thus, the introduction of α -syn aggregates had no
401 effect on the electrotonic properties of the neurons, by for example electrically isolating
402 compartments. Aggregated α -syn markedly increased the membrane conductance (272 %
403 of the conductance at 0 mins by 32 minutes, $P = 0.001$, Fig 5D). In control neurons (vehicle
404 or α -syn monomers) there was a small increase in conductance (vehicle conductance was
405 135 % of the conductance at 0 mins by 32 minutes $P = 0.009$; α -syn monomer conductance
406 was 141.2 % of the conductance at 0 mins by 32 minutes, ns) over the duration of
407 recordings. At 32 minutes there was no significant ($P > 0.9999$) difference between the
408 conductance of vehicle and α -syn monomer treated neurons. In contrast, the conductance of
409 α -syn aggregate treated neurons was significantly ($P = 0.0003$) larger than vehicle treated
410 neurons. There was no significant differences in the other extracted parameters: resting
411 membrane potential, spike potential or spike-resting potential between the 3 experimental

412 conditions (Fig 5F-H). Thus the reduction in excitability induced by α -syn aggregates is only
413 due to a change in conductance rather than changes in for example the potential difference
414 between rest and threshold.

415 **The decrease in conductance and firing rate caused by alpha synuclein is in part due**
416 **to the opening of KATP channels**

417 Previous studies have shown that either blocking ATP-sensitive K channels (KATP) or
418 genetically deleting them it has protective effects on dopaminergic neurons in PD rodent
419 models (Liss et al 2005; Zhang et al 2012). There has also been a recent preprint that shows
420 that the effects of α -syn aggregates on spontaneous firing can be prevented by blocking
421 KATP channels (Thakur et al, 2019). To investigate whether the increase in membrane
422 conductance that we have observed could be prevented by inhibiting KATP channel
423 opening, we used the classic KATP blocker glibenclamide (Light and French 1994; Jiang
424 and Haddad 1997). We first investigated whether the presence of glibenclamide throughout
425 recordings had any effect on the electrophysiological properties of SNpc dopaminergic
426 neurons (Fig 6A). There was no significant difference in any of the measured parameters
427 (from SIVs, membrane potential $P = 0.3791$, resistance $P = 0.2294$, firing rate $P = 0.6548$) at
428 0 mins between neurons from slices which had been pre-incubated with glibenclamide (1
429 μM , $n = 6$) compared to neurons in control slices (both with vehicle in the patch pipette).
430 These neuronal parameters did not significantly change over the duration of the recordings
431 with glibenclamide present: resistance (after 32 mins $99 \pm 7.5\%$ of the resistance at time 0
432 mins, $P = 0.08438$, $n = 6$) or firing rate (after 32 mins $112.1 \pm 26.6\%$ of the firing rate at time
433 0 mins, $P = 0.5625$, Fig 6A). Thus, glibenclamide had no significant effect on neuronal
434 properties measured from SIVs that could occlude the actions of α -syn aggregates.

435 We then made whole-cell recordings with α -syn aggregates in the patch pipette in slices pre-
436 incubated in glibenclamide (1 μM , Fig 6B). The fall in resistance and firing rate that was
437 observed in the presence of α -syn aggregates did not occur when the slices were incubated

438 with glibenclamide. There was no significant reduction in resistance or firing rate over the
439 duration of recording when slices were incubated with glibenclamide suggesting that the
440 action of α -syn aggregates could least in part be mediated by KATP channels. The
441 resistance at 32 mins was 90 ± 8.62 % of the resistance at time 0 mins (cf 63 % without
442 glibenclamide) which was not statistically significant ($P = 0.25$, $n = 6$) from the resistance at
443 time zero. The firing rate was 80.14 ± 12.89 % of the rate at time 0 mins (vs 42 % without
444 glibenclamide) which was not statistically significant from the firing rate at time 0 mins ($P =$
445 0.353 , $n = 6$). Both sets of recorded neurons (vehicle and α -syn aggregates) weakly
446 depolarised over the 32 minutes of recording to a similar degree to that of non-glibenclamide
447 treated slices (vehicle, ΔV_m 4.66 ± 2.6 mV and α -syn aggregates, ΔV_m 5.5 ± 2.05 mV, Fig
448 6E).

449 We further investigated the effects of the glibenclamide on the effects of α -syn aggregates -
450 using the dynamic IV (DIV). The DIV curves in glibenclamide (vehicle) and in glibenclamide
451 (α -syn aggregates) did not markedly change throughout the duration of the recordings (Fig
452 7A, B). As observed previously (without glibenclamide) there was also no change in
453 capacitance over the duration of the recordings ((vehicle $P = 0.0625$, α -syn aggregates $P =$
454 0.0625 , Fig 7C). In the presence of glibenclamide, there was no significant increase ($P =$
455 0.0625) in whole cell conductance for vehicle receiving neurons over the duration of the
456 recordings or only a small increase for α -syn aggregate receiving neurons ($P = 0.0313$).
457 After 32 minutes, there was no significant ($P = 0.3095$) difference between the whole cell
458 conductance of neurons receiving vehicle and those receiving α -syn aggregates (Fig 7D, H).
459 For all the other extracted parameters there was no difference between vehicle and α -syn
460 aggregate receiving neurons for the duration of recordings (Fig 7E-G). Thus, as observed
461 with SIV analysis, the KATP inhibitor glibenclamide significantly reduced the effects of α -syn
462 aggregates.

463

464

465 **Discussion**

466 In this study we have used whole-cell patch-clamp recording to introduce a known
467 concentration and form of aggregated alpha synuclein (α -syn) into single substantia nigra
468 pars compacta (SNpc) dopaminergic neurons in acutely isolated mouse slices. Although it is
469 possible, using emerging technologies, to isolate only the oligomeric fractions (Kumar et al,
470 2020) we have not utilised such methods. Thus we cannot exclude the possibility that some
471 small fibrils are present in our α -syn oligomer samples. While the majority of the species in
472 our α -syn samples appeared to have an oligomeric structure (Fig 3) other forms of small
473 aggregates maybe present (for example small ~50 nm fibrils; Polinski et al, 2018). We have
474 therefore used the term α -syn aggregates rather than α -syn oligomers. As outlined in
475 previous studies (Kaufmann et al 2016; Hill et al 2019) delivery of species via the patch
476 pipette has a number of advantages, the main one being that it is possible to measure early
477 changes in the properties of a single neuron in a network that is free from pathology. This
478 method also bypasses any slow uptake steps and each neuron acts as its own control, as at
479 early time points only low concentrations of the species will have diffused into the neuron.
480 Here we have introduced 500 nM of α -syn aggregates, which is a concentration in line with
481 previous studies (see Kaufmann et al, 2016). However, as noted in the methods, the actual
482 concentration of aggregates will be considerably lower. It would be interesting in future
483 experiments to investigate whether there is a concentration dependant effect of α -syn
484 aggregates, with for example lower concentrations having a slower onset (see Hill et al
485 2019).

486 We used both standard current-voltage relationships (SIV, with step current injections) and
487 the dynamic current-voltage relationships (DIV, with naturalistic current injection) to extract
488 neuronal parameters. Both approaches measured a marked increase in whole-cell
489 conductance (fall in neuronal resistance), which occurred between 8-16 minutes after whole-

490 cell break through. There were no significant changes in membrane potential, cell
491 capacitance or spike threshold between neurons receiving α -syn aggregates, α -syn
492 monomers or vehicle. The increase in conductance significantly reduced the firing rate, both
493 induced (by current injection) and spontaneous, and abolished rebound firing following
494 hyperpolarising current steps. The increase in conductance increased the linearity of the DIV
495 curve effectively shunting the depolarisation-activated conductance increase just below
496 threshold that was present in some neurons at 0 minutes (whole-cell breakthrough).

497 Obtaining similar results using two independent methods for the extraction of neuronal
498 parameters strengthens the robustness of the observation that α -syn aggregates increase
499 whole-cell conductance. There were minor differences in the precise values of the neuronal
500 parameters extracted using DIV compared to those extracted with SIV, which is to be
501 expected given the different conductance states of the cell in the two protocols. For the DIV,
502 the voltage varies across a wide range during naturalistic stimulation (mimicking in vivo
503 synaptic activity) activating and inactivating a variety of conductances. In contrast the SIV
504 extracts parameters over a much smaller range of voltages from essentially quiescent cells.
505 For example, if the DIV and SIV curves are compared, the DIV conductances are initially
506 lower (at 0 minutes) for all of the experimental conditions (vehicle, aggregates and
507 monomers) and then increase. This could be interpreted as one or more of the
508 conductances being slightly more inactivated during the DIV protocol. It could then be that
509 this inactivation is relieved as the neuronal resting potential slowly depolarises during the
510 recording. Alternatively, it could be that another conductance activates as the neuron
511 depolarises, but in a range that is not accessed by the hyperpolarising SIV current steps. In
512 either case, a different range of voltages is probed between DIV and SIV and so differences
513 in the extracted parameters will occur. The fact that the same significant conductance
514 increase (resistance decrease) is clearly seen in these two very different protocols attests to
515 the robustness of the effect of alpha-synuclein on these neurons.

516

517

518 **The increase in whole-cell conductance is reduced by the KATP channel blocker**
519 **glibenclamide**

520 The effects of the ATP-sensitive K⁺ channel (KATP) inhibitor glibenclamide (Light and
521 French 1994) suggests the involvement of KATP channels (but see caveats below). KATP
522 channels are inwardly rectifying K⁺-selective ion channels that are inhibited by intracellular
523 ATP. KATP channels provide a link between the energy state of cells and their electrical
524 activity acting as a metabolically controlled “brake on excitation”. A decrease in sub-
525 membrane ATP levels and an accompanying rise in ADP concentration (during activity)
526 triggers KATP channel opening dropping neuronal resistance and hyperpolarising the
527 membrane potential (Stanford and Lacey 1995; Seino, 1999; Haller et al., 2001). It is well
528 established that SNpc dopaminergic neurons express KATP channels (Schiemann et al
529 2012; Liss et al 2005). The lack of effect of the KATP inhibitor glibenclamide under control
530 conditions suggests that few KATP channels are open at rest. This is perhaps not surprising
531 as there was 2 mM ATP in the intracellular patch solution, although some KATP channels
532 have a low affinity for ATP and would still be open with this level of ATP (for example see
533 Allen and Brown 2004). The effects of α -syn aggregates on conductance and its inhibition
534 by glibenclamide are consistent with the opening of KATP channels (but see below). These
535 effects occurred in the presence of 2 mM intracellular ATP suggesting a direct effect of α -
536 syn aggregates on the KATP channel, rather than via a reduction in intracellular ATP
537 concentration (by for example mitochondrial dysfunction). KATP channel openers like
538 diazoxide have previously been shown to act by open KATP channels in the presence of
539 ATP (Schwanstecher et al 1998) so it is possible that α -syn aggregates could have a similar
540 action.

541 The effects on cell conductance and its prevention with glibenclamide are consistent with the
542 α -syn aggregates increasing KATP channel open probability. However, there was little or no

543 associated membrane potential hyperpolarisation (measured with SIV and with DIV), which
544 has been observed in most reports of KATP channel activation (for example see Stanford
545 and Lacey, 1995; Allen and Brown 2004). The equilibrium potential for K^+ is ~ -95 mV, so
546 opening of KATP channels would be expected to produce a large hyperpolarisation of the
547 membrane potential (as the resting potential at time zero was ~ -55 mV). However, the
548 membrane potential hyperpolarisation could possibly be counteracted by the opposing
549 activation of hyperpolarization-activated, cyclic nucleotide-gated HCN channels $I(h)$ which
550 have a reversal potential between -40 to -30 mV (Mayer and Westbrook 1983). It may be
551 that the opening of a relatively small number of KATP channels changes the input
552 resistance/conductance of neurons but is insufficient to change the membrane potential
553 against the responsive reaction of $I(h)$. In contrast opening of many KATP channels will
554 overcome the effects of $I(h)$ leading to robust membrane hyperpolarisation, which as
555 reported for SNpc dopaminergic neurons by lowering intracellular ATP concentration or
556 using KATP channel opening drugs (Stanford and Lacey 1995).

557 The inhibitory effects of glibenclamide on α -syn responses are consistent with the opening of
558 KATP channels but additional evidence is required to provide definitive evidence for a role
559 for KATP channels in the effects of α -syn aggregates. One possible approach is to occlude
560 the effects of α -syn aggregates using a pharmacological opener of KATP channels (such as
561 diazoxide). However these experiments maybe be difficult to interpret. The KATP channel
562 opener will markedly reduce resistance and hyperpolarise the recorded neuron. This may
563 occlude the effects of α -syn aggregates simply by shunting the neuron and moving it closer
564 to E_K rather than acting through the same channel. Other possible approaches include the
565 use of transgenic animals, where the KATP gene has been deleted, or using cell lines
566 expressing specific KATP channels. Alternate possibilities for the lack of membrane
567 hyperpolarisation include the opening of other channels that depolarise the neuron. For
568 example, it has been reported that α -synuclein itself can form non-selective cation channels
569 (Mironov et al, 2015).

570 It took on average between 8-16 minutes of dialysis for the effects of α -syn aggregates on
571 whole cell conductance to become significant. It may be that the concentration within the
572 neuron has to reach a sufficient level to open membrane channels. For comparison
573 introduction of aggregated tau (444 nM) into pyramidal neurons started to have effects on
574 the action potential within the first 10 minutes (Hill et al, 2019). In this study we chose to
575 focus on the effects of introducing α -syn aggregates into substantia nigra dopaminergic
576 neurons. Given that the neighbouring population of VTA dopaminergic neurons have
577 differences in their KATP channel expression (Liss et al, 2005), it might be expected that α -
578 syn aggregates may have a different effect in these cells (which would additional evidence
579 for a role of KATP channels). This may contribute to the varying vulnerability of these two
580 dopaminergic nuclei in diseases like Parkinson's disease.

581 The accumulation of α -syn aggregates in SN dopaminergic neurons during Parkinson's
582 disease progression could potentially result in the prolonged activation of membrane
583 channels (such as KATP) which will chronically reduce electrical activity, the amount of
584 dopamine released (Patel et al, 2011) and will be detrimental to neuron function. If KATP
585 channels are involved then there will be a loss of the metabolic feedback mechanism.
586 Consistent with this KATP involvement, there is retrospective epidemiological evidence of a
587 reduced risk for Parkinson's disease in type 2 diabetic patients that were treated with KATP
588 inhibitors (Schernhammer *et al*, 2011; Wahlqvist *et al*, 2012; Cereda *et al*, 2013; Lu *et al*,
589 2014; Brauer *et al*, 2015).

590 **Conclusion**

591 In this study we have combined electrophysiological recording with detailed and thorough
592 analysis to characterize the effects of introducing aggregated α -Syn directly into single
593 mouse dopaminergic neurons in the substantia nigra. Aggregated α -Syn caused a significant
594 increase in conductance and decrease in firing rate without altering the resting membrane
595 potential, capacitance or spike threshold. Changes to conductance and firing rate occurred

596 8-16 minutes after whole-cell breakthrough and were specific to aggregates (they were not
597 observed when monomeric alpha synuclein was introduced). The effects could be prevented
598 by pre-incubating the slices in ATP-sensitive potassium channel (K_{ATP}) inhibitor
599 glibenclamide, despite the high concentration of ATP present in the patch electrode. This
600 suggests that aggregated α -Syn may increasing the opening probability of K_{ATP} channels,
601 resulting in an increase in conductance, a reduction in neuronal excitability and likely also a
602 decrease in dopamine release and overall cell function.

603 **References**

604 Alderson TR, Markley JL (2013) Biophysical characterization of α -synuclein and its
605 controversial structure. *Intrinsically Disord Proteins*. 1(1):18-39.

606 Allen TG, Brown DA. (2004) Modulation of the excitability of cholinergic basal forebrain
607 neurones by K_{ATP} channels. *J Physiol*. 554(Pt 2):353-70.

608 Badel L, Lefort S, Brette R, Petersen C, Gerstner W, Richardson, M (2008a). Dynamic I-V
609 Curves Are Reliable Predictors of Naturalistic Pyramidal-Neuron Voltage Traces. *Journal of*
610 *Neurophysiology*, 99(2): 656-666.

611 Badel L, Lefort S, Berger T, Petersen C, Gerstner, W, Richardson, M (2008b). Extracting
612 non-linear integrate-and-fire models from experimental data using dynamic I-V
613 curves. *Biological Cybernetics*, 99(4-5): 361-370.

614 Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain
615 dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and
616 neurochemical correlations. *Journal of the Neurological Sciences*. 20(4):415-455

617 Bengoa-Vergniory, N., Roberts, R., Wade-Martins, R. and Alegre-Abarrategui, J., 2017.
618 Alpha-synuclein oligomers: a new hope. *Acta Neuropathologica*, 134(6), pp.819-838.

619 Bezanson J, Edelman A, Karpinski S, Shah VB (2014) Julia: A fresh approach to numerical
620 computing. *SIAM review*. ;59(1):65-98.

- 621 [Brauer R](#), Bhaskaran K, Chaturvedi N, Dexter DT, Smeeth L., Douglas I (2015) Glitazone
622 Treatment and Incidence of Parkinson's Disease among People with Diabetes: A
623 Retrospective Cohort Study. *PLoS Med* 12(7):e1001854.
- 624 Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Suedhof TC (2010) alpha
625 Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro. *Science* 329:1663-
626 1667.
- 627 Cereda E, Barichella M, Pedrolli C, Klersy C, Cassani E, Caccialanza R, Pezzoli G. (2012)
628 Diabetes and risk of Parkinson's disease. *Mov Disord.* 28(2):257
- 629 Damier P, Hirsch EC, Agid Y, Graybiel AM (1999) The substantia nigra of the human brain.
630 II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. *Brain.* 122:1437-
631 1448.
- 632 Grace AA, Onn SP (1989) Morphology and electrophysiological properties of
633 immunocytochemically identified rat dopamine neurons recorded in vitro. *J Neurosci*
634 (10):3463-81.
- 635 Haller M, Mironov SL, Karschin A, Richter DW (2001) Dynamic activation of K(ATP)
636 channels in rhythmically active neurons. *J Physiol.* 537(Pt 1):69-75
- 637 Harris NC, Constanti A (1995) Mechanism of block by ZD 7288 of the hyperpolarization-
638 activated inward rectifying current in guinea pig substantia nigra neurons in vitro. *J*
639 *Neurophysiol.* 74(6):2366-78.
- 640 Harris N, Webb C, Greenfield S, (1989) A possible pacemaker mechanism in pars compacta
641 neurons of the guinea-pig substantia nigra revealed by various ion channel blocking agents.
642 *Neuroscience* 31(2): 355-362.
- 643 Harrison PM, Badel L, Wall MJ and Richardson MJE (2015) Experimentally verified
644 parameter sets for modelling heterogeneous neocortical pyramidal-cell populations *PLOS*
645 *Computational Biol* 11: e1004165

- 646 He C, Chen F, Li B, Hu Z (2014) Neurophysiology of HCN channels: from cellular functions
647 to multiple regulations. *Prog Neurobiol* 112:1-23.
- 648 Hill E, Karikari TK, Moffat G, Richardson MJE, Wall MJ (2019) Introduction of tau oligomers
649 into cortical neurons alters action potential dynamics and disrupts synaptic transmission and
650 plasticity. *eNeuro* .0166-19.2019,
- 651 Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A, Saitoh T (1995)
652 The precursor protein of non-A beta component of Alzheimer's disease amyloid is a
653 presynaptic protein of the central nervous system. *Neuron*. 14(2):467-75.
- 654 Jakes R, Spillantini MG, Goedert M (1994) Identification of 2 distinct synucleins from human
655 brain. *FEBS Letters* 345:27-32.
- 656 Kaufmann TJ, Harrison P, Richardson MJE, Pinheiro TJT, Wall MJ (2016) Intracellular
657 injection of soluble alpha synuclein oligomers reduces pyramidal cell input resistance and
658 firing rate. *J Physiol* 594 (10): 2751-2772
- 659 Kumar, S. T., Donzelli, S., Chiki, A., Syed, M. M. K., & Lashuel, H. A. (2020). A simple,
660 versatile and robust centrifugation-based filtration protocol for the isolation and quantification
661 of α -synuclein monomers, oligomers and fibrils: Towards improving experimental
662 reproducibility in α -synuclein research. *Journal of Neurochemistry*.
- 663 Jiang C, Haddad GG (1997) Modulation of K⁺ channels by intracellular ATP in human
664 neocortical neurons. *J Neurophysiol*. 77(1):93-102.
- 665 Krashia P, Martini A, Nobili A, Aversa D, D'Amelio M, Berretta N, Guatteo E, Mercuri NB.
666 (2017) On the properties of identified dopaminergic neurons in the mouse substantia nigra
667 and ventral tegmental area. *Eur J Neurosci* .45(1):92-105.
- 668 Lacey MG, Mercuri NB, North RA (1989) Two cell types in rat substantia nigra zona
669 compacta distinguished by membrane properties and the actions of dopamine and opioids.
670 *J Neurosci*. 9(4):1233-41.

- 671 Lashuel HA, Overk CR, Oueslati A, Masliah E (2013) The many faces of alpha synuclein:
672 from structure and toxicity to therapeutic target. *Nature Reviews Neuroscience* 14:38-48
- 673 Light PE, French RJ (1994) Glibenclamide selectively blocks ATP-sensitive K⁺ channels
674 reconstituted from skeletal muscle. *Eur J Pharmacol* 259(3):219-22.
- 675 Liss B, Haeckel O., Wildmann J., Miki T., Seino S., Roper J. (2005) K-ATP channels
676 promote the differential degeneration of dopaminergic midbrain neurons. *Nature Neurosci*
677 8(12):1742-51.
- 678 Lu L, Fu DL, Li HQ, Liu AJ, Li JH, Zheng GQ. (2014) Diabetes and risk of Parkinson's
679 disease: an updated meta-analysis of case-control studies. *PLoS One*. 21;9(1):e85781.
- 680 Mahul-Mellier, A., Bartscher, J., Maharjan, N., Weerens, L., Croisier, M., Kuttler, F., Leleu,
681 M., Knott, G. and Lashuel, H., 2019. The process of Lewy body formation, rather than simply
682 alpha-synuclein fibrillization, is the major driver of neurodegeneration in synucleinopathies.
- 683 Mayer M.L., Westbrook G.L. 1983. A voltage-clamp analysis of inward (anomalous)
684 rectification in mouse spinal sensory ganglion neurones. *J. Physiol.* 340:19–45
- 685 Michel PP, Hirsch EC, Hunot S (2016) Understanding Dopaminergic Cell Death Pathways in
686 Parkinson Disease. *Neuron*. 90(4):675-91.
- 687 Mironov S (2015) α -Synuclein forms non-selective cation channels and stimulates ATP-
688 sensitive potassium channels in hippocampal neurons. *J Physiol* 593(1):145-59.
- 689 Murphy DD, Rueter SM, Trojanowski JQ, Lee VMY (2000) Synucleins are developmentally
690 expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in
691 primary hippocampal neurons. *Journal of Neurosci* 20:3214-3220.
- 692 Neuhoff H, Neu A, Liss B, Roper J (2002) I(h) channels contribute to the different functional
693 properties of identified dopaminergic subpopulations in the midbrain. *J Neurosci*. 22(4):1290-
694 302

- 695 Patel JC, Witkovsky P, Coetzee WA, Rice ME (2011) Subsecond regulation of striatal
696 dopamine release by pre-synaptic KATP channels. *J Neurochem.* 118(5):721-36
- 697 Polinski NK, Volpicelli-Daley LA, Sortwell CE, Luk KC, Cremades N, Gottler LM, Froula J,
698 Duffy MF, Lee VMY, Martinez TN, Dave KD (2018) Best Practices for Generating and Using
699 Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents. *J*
700 *Parkinson's Dis.* 8(2):303-322.
- 701 Richards CD, Shiroyama T, Kitai ST. (1997) Electrophysiological and immunocytochemical
702 characterization of GABA and dopamine neurons in the substantia nigra of the rat.
703 *Neuroscience.* 80(2):545-57.
- 704 Schernhammer E, Hansen J, Rugbjerg K, Wermuth L, Ritz B. Diabetes and the risk of
705 developing Parkinson's disease in Denmark. *Diabetes Care* 34(5):1102-8.
- 706 Schiemann J, Schlaudraff F, Klose, V, Bingmer M, Seino S, Magill P, Zaghloul KA,
707 Schneider G, Liss B, Roeper J (2012) K-ATP channels in dopamine substantia nigra
708 neurons control bursting and novelty-induced exploration *Nat Neurosci.* 15(9):1272-80.
- 709 Schwanstecher M, Sieverding C, Dorschner H, et al. (1998) Potassium channel openers
710 require ATP to bind to and act through sulfonylurea receptors. *EMBO J.* 1998;17(19):5529–
711 5535
- 712 Seino S (1999) ATP-sensitive potassium channels: a model of heteromultimeric potassium
713 channel/receptor assemblies. *Annu Rev Physiol.* 61:337-62.
- 714 Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M (1997) α -
715 Synuclein in Lewy bodies. *Nature.* 388:839–840.
- 716 Stanford IM, Lacey MG (1995) Regulation of a potassium conductance in rat midbrain
717 dopamine neurons by intracellular adenosine triphosphate (ATP) and the sulfonylureas
718 tolbutamide and glibenclamide. *J Neurosci.* 15(6):4651-7.

719 Thakur P, Luk K, Roeper J (2019). Selective K-ATP channel-dependent loss of pacemaking
720 in vulnerable nigrostriatal dopamine neurons by α -synuclein aggregates. [*preprint* doi:
721 <https://doi.org/10.1101/842344>]

722 Wahlqvist M, Lee MS, Hsu CC, Chuang SY, Lee Jy, Tsai HN (2012) Metformin-inclusive
723 sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes
724 in a Taiwanese population cohort. *Parkinsonism Relat Disord* 18(6):753-8.

725 Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T, Vilar M,
726 Campioni S (2011) In vivo demonstration that α -synuclein oligomers are toxic. *Proc. Natl.*
727 *Acad. Sci. USA.* 108:4194–4199.

728 Zhang Q, Li C, Zhang T, Ge Y, Han X, Sun S, Ding J, Lu M, Hu G (2018) Deletion of
729 Kir6.2/SUR1 potassium channels rescues diminishing of DA neurons via decreasing iron
730 accumulation in PD. *Mol Cell Neurosci.* 164-176.

731

732 **Legends**

733 **Figure 1: Whole-cell patch-clamp recording from dopaminergic neurons in the SNpc**

734 (A) Example membrane potential trace recorded from a putative dopaminergic neuron (DN)
735 in the substantia nigra which showed characteristic spontaneous action potential firing.
736 Dopamine (30 μ M) hyperpolarised the neuron from -62 mV to -70 mV and stopped the action
737 potential firing. (B) The different input currents delivered to putative DNs. SIV is the standard
738 step current protocol, 3 s duration steps starting at -200 pA and increasing by 50 pA until the
739 neuron exhibits a regular firing pattern. DIV uses a fluctuating naturalistic noisy current trace
740 (see methods for details) which is also used to determine action potential firing rate. (C)
741 (Top) Membrane potential traces in response to current steps. The recorded neuron displays
742 characteristic features of DNs: a large sag in response to hyperpolarising steps (arrow) and
743 rebound firing (*). (Bottom) Membrane potential trace from the same cell in response to
744 naturalistic current injection. The neuron can be seen to be firing at rest (*) which is a

745 characteristic feature of these neurons. (D) (Top) Membrane potential traces in response to
746 current steps following application of dopamine (30 μ M). The sag is reduced, the membrane
747 potential hyperpolarised, the firing reduced, and the rebound firing is absent. (Bottom)
748 Membrane potential trace from the same cell in response to naturalistic current injection in
749 dopamine (30 μ M). The neuron has stopped firing at rest, fires less frequently during current
750 application and is hyperpolarised. (E) (Top) Membrane potential traces in response to
751 current steps in the presence of the I(h) blocker ZD7288 (100 μ M) are similar to that
752 previously reported for DN (Harris and Constanti, 1995). The sag response to
753 hyperpolarising current steps is markedly reduced, the resting membrane potential is
754 hyperpolarised, the firing rate reduced and the voltage response following the spike is
755 altered. (Bottom) Membrane potential response of the same neuron to the naturalistic
756 injected current in ZD7288 (100 μ M). (F) Tyrosine hydroxylase (TH) immunohistochemistry
757 confirms that the recorded neurons were DNs. Neurons were filled with AF594 dye (red) via
758 the patch pipette and then slices were stained for TH (green). The merged image shows that
759 the recorded neurons express tyrosine hydroxylase and are therefore dopaminergic. The
760 scale bar is 50 μ m.

761

762 **Figure 2: Extracting neuronal parameters using standard-IV (SIV, panel A) and**
763 **dynamic-IV (DIV, panels B-D) methodologies.** For the SIV measurements: (A) Applied
764 current and voltage response. Arrow shows location of voltage measurement for the
765 calculation of neuronal resistance (peak voltage deflection). For the dynamic IV
766 measurements: (B) Naturalistic stimulation current and voltage response. (C) The estimated
767 ionic current as a scatter plot against voltage (points). The dynamic-IV curve (black) is the
768 typical ionic current at a particular voltage where data within 200 ms post-spike was not
769 included to avoid the effects of transitory spike-generated currents. (D) The dynamic IV
770 curve (black) and its linear fit to the ohmic component (green, from hyperpolarised voltages

771 to the resting voltage). Inset, illustrates the isolated outward current. See Methods for further
772 details of the SIV and DIV fitting procedures.

773 **Figure 3: Structural analysis of alpha synuclein samples.**

774 Electron micrographs of negative-stain-TEM analysed protein samples. The sample (5 μ l)
775 was applied onto a copper grid and fixed with uranyl acetate. Magnification is 60,000x. (A)
776 Tau aggregates (for reference) showing aggregated form. Inset, higher magnification
777 showing annular form of aggregates (B) Alpha synuclein monomers show no aggregation.
778 Inset, higher magnification showing no structural form (C) Alpha synuclein aggregates
779 display many large fibrils (preformed fibrils PFF). Inset, example of fibrils at higher
780 magnification (D) Alpha synuclein fibrils were added to intracellular patch solution and then
781 sonicated for 15 minutes to form small aggregates. Inset, illustrates the annular form of
782 aggregates. Scale bar = 200 nm.

783

784 **Figure 4. Alpha-synuclein aggregates induce a time-dependent decline in firing rate**
785 **and significant fall in neuronal resistance.**

786 Example current-voltage relationships (SIV) for dopaminergic neurons injected with α -syn
787 aggregates (A), vehicle (B) and α -syn monomers (C). Current steps (starting at -200pA and
788 increasing by 50 pA until a regular firing pattern was induced) were used to construct SIVs.
789 Recordings display SIVs at time points between whole cell breakthrough (0 mins) and up to
790 32 mins. The neuron which had the α -syn aggregates introduced (A) shows a clear
791 reduction in the voltage responses and a fall in the firing rate at positive potentials, whereas
792 the neurons that received either vehicle or α -syn monomers show no significant changes (B,
793 C). (D) Mean neuronal resistance plotted against time for control (vehicle) neurons and
794 neurons that had either α -syn aggregates or monomers introduced. For the neurons injected
795 with α -syn aggregates, after 32 minutes of recording, the resistance was significantly ($p =$

796 0.0029) reduced to 63 ± 9.21 % of the resistance measured at 0 mins. At the 32-minute time
797 point there was a significant ($P = 0.0002$) difference in resistance between the neurons that
798 received α -syn monomers or vehicle to those where α -syn aggregates were introduced. (E)
799 Mean resting membrane potential plotted against time for control (vehicle) neurons and
800 neurons that had either α -syn aggregates or monomers introduced. Under all experimental
801 conditions, the neurons slowly depolarised over the time course of the recording. For
802 vehicle, the mean depolarisation (ΔV_m) was 6.2 ± 1.82 mV after 32 minutes of recording (P
803 = 0.0234), for α -syn monomers ΔV_m was 3.8 ± 1.2 mV ($P = 0.0938$) and for α -syn
804 aggregates ΔV_m was 6.8 ± 1.85 mV ($P = 0.0107$). (F) Normalised firing rate plotted against
805 time for control (vehicle) neurons and neurons that had either α -syn aggregates or
806 monomers introduced (firing rate was measured from naturalistic current injection). Data is
807 normalised to the firing rate at time 0 (whole cell break through). Despite depolarising by a
808 comparable amount to the control (vehicle) and monomer introduced neurons, α -syn
809 aggregates induced a significant reduction in the firing rate over time ($P=0.0020$) consistent
810 with the fall in input resistance. When comparing control (vehicle and α -syn monomers) and
811 α -syn aggregates there was a significant difference in the firing rate at 32 minutes ($P =$
812 0.0061). (G) The same section of voltage trace taken during the injection of naturalistic
813 current in example neurons injected with vehicle, α -syn monomers and α -syn aggregates to
814 illustrate the changes in firing pattern over the duration of recordings.

815

816 **Figure 5. Intracellular diffusion of alpha-synuclein aggregates results in a progressive**
817 **conductance increase in the dynamic I-V curve.**

818 Example dynamic IV curves (DIV) from neurons that had control (vehicle, A), alpha-
819 synuclein (α -syn) aggregates (B) or monomeric α -syn (C) introduced. Each graph shows the
820 DIV curve at 8 minute time points throughout recordings (32 minutes). There is a marked
821 increase in the gradient of the DIV (conductance) when oligomeric α -syn was introduced. (D-

822 H) Extracted neuronal parameters averaged across recordings for the time periods during
823 recordings ($n = 10$ for control, $n = 11$ α -syn aggregates and $n = 6$ α -syn, monomers).
824 Capacitance (D) showed no significant change over time for all the experimental conditions.
825 Though both control (vehicle) and monomeric α -syn neurons showed a small increase in
826 conductance (E) over time (~35% and ~40% after 32 minutes, respectively), the average
827 conductance for the cells receiving α -syn aggregates was almost threefold its initial value by
828 32 mins (~170 % increase; $P=0.009$). At 32 minutes there was no significant ($P > 0.9999$)
829 difference between the conductance of vehicle and α -syn monomer treated neurons. In
830 contrast, the conductance of α -syn aggregate treated neurons was significantly ($P = 0.0003$)
831 larger than vehicle treated neurons. Though both the resting potential (F) and spike
832 threshold (G) slightly increased with time, the potential difference from resting potential to
833 spike threshold remained constant with time. The decrease in excitability of the cells
834 receiving α -syn aggregates was therefore mediated by a conductance shunt rather than an
835 increase in the relative threshold for spike initiation.

836 **Figure 6. The effects of alpha-synuclein aggregates on electrophysiological properties**
837 **are reversed by glibenclamide**

838 (A) Standard current-voltage relationship (SIV) for an example control neuron (injected with
839 vehicle) in the presence of the KATP channel inhibitor glibenclamide ($1\mu\text{M}$). Current steps
840 (starting at -200pA and rising by 50 pA) were injected until a regular firing pattern was
841 induced. SIV traces are displayed at time points between whole cell breakthrough (0 mins)
842 and the end of recording (32 mins). The neuron remained stable for the duration of the
843 recording with little change in the SIV. (B) As in (A), but with α -syn aggregates (500 nM, final
844 concentration) added to the internal recording solution. The decrease in input resistance and
845 firing rate that was observed with α -syn aggregates in control conditions was markedly
846 reduced by the presence of glibenclamide. (C) Mean resistance measurements over time
847 for control (vehicle) vs α -syn aggregates in the presence of glibenclamide. The fall in

848 resistance was reduced compared to that for α -syn aggregate-injected neurons recorded in
849 normal aCSF. (D) Mean resting membrane potential measurements plotted against time for
850 vehicle vs α -syn aggregates in the presence of glibenclamide. (E) Mean firing rate
851 (measured from naturalistic current injection) plotted against time for vehicle vs α -syn
852 aggregates in the presence of glibenclamide. The fall in firing rate was reduced compared to
853 that for α -syn aggregate-injected neurons in normal aCSF. The red dotted line represents
854 the effects observed with the introduction of α -syn aggregates in the absence of
855 glibenclamide, this data is repeated from Figure 4 and is intended to provide a visual
856 reference to demonstrate the partial recovery.

857 **Figure 7. The KATP channel inhibitor glibenclamide blunts the effects of α -syn**
858 **aggregates on the DIV.**

859 Slices were incubated in glibenclamide (1 μ M) to block KATP channels. (A) Example
860 dynamic IV curves for a neuron that had vehicle introduced. (B) Example dynamic IV curves
861 for a neuron that had α -syn aggregates introduced. For (A and B) each graph shows the DIV
862 curves at 8 minute time points throughout recordings (32 minutes). There are no marked
863 changes in the DIV across time for the two experimental conditions. (C-H) Extracted
864 neuronal parameters averaged across recordings for the time periods during recordings ($n =$
865 6 for vehicle, $n = 6$ α -syn aggregates). Capacitance (C) showed no significant change over
866 time for all the experimental conditions. (D) There was a small increase in whole-cell
867 conductance for neurons with α -syn aggregates, but the percentage change was closer to
868 vehicle than to α -syn aggregates without glibenclamide. Resting potential (F) and spike
869 threshold (G) also slightly increased with time, the potential difference from rest potential to
870 spike threshold remained constant with time. (H) Graph plotting the normalised conductance
871 (normalised to the conductance at time 0 mins) for all experimental conditions. Using a
872 Kruskal Wallis ANOVA, we confirmed that both time and experimental condition had a
873 significant effect on conductance ($P < 0.0001$ and $P < 0.0001$ respectively). At 32 mins, the

874 neurons with α -syn aggregates injected have a significantly greater conductance than any of
875 the other experimental conditions (vs control $P < 0.0001$, vs monomer $P = 0.0003$, vs Glib +
876 control $P < 0.0001$, vs Glib + aSyn $P = 0.0045$; Dunn's post hoc analysis). No other
877 experimental conditions were significantly different from each other.

878

879

Table 1

880

881

882

883

884

885

886

887

Parameter	Vehicle/ control			aSyn aggregates			aSyn monomers			Glib + vehicle			Glib + aSyn aggregates		
	Mean	SEM	SD	Mean	SEM	SD	Mean	SEM	SD	Mean	SEM	SD	Mean	SEM	SD
RMP (mV)	-55.8	± 1.2	± 3.79	-55.4	± 1.23	± 4.10	-56.8	± 1.30	± 3.18	-53.2	± 2.14	± 5.24	-60.4	± 1.82	± 4.08
R in (MΩ)	338	± 17.6	± 55.8	312	± 17.1	± 56.8	359	± 42.2	± 103.3	386	± 25.2	± 61.7	294	± 41.9	± 93.6
Firing Rate (Hz)	1.63	± 0.39	± 0.12	2.51	± 1.57	± 0.47	2.38	± 1.14	± 0.46	2.27	± 1.15	± 0.47	2.04	± 1.29	± 0.52
C (pF)	88.8	± 5.74	± 14.1	107.8	± 5.84	± 14.3	80.73	± 15.1	± 37.0	81.16	± 8.54	± 20.9	117	± 22.3	± 54.7
g (nS)	2.29	± 0.2	± 0.49	2.78	± 0.2	± 0.49	1.99	± 0.3	± 0.73	2.39	± 0.29	± 0.71	3.67	± 0.55	± 1.35

888

Table 1: Electrophysiological parameters measured for dopaminergic neurons at time zero for all experimental treatments


Data	Figure	Statistical Test	Test values	P value
0 mins, all conditions, RMP	Figure 4	Kruskal-Wallis ANOVA	H (4) = 0.5385	P = 0.4657
0 mins, all conditions, IR	Figure 4	Kruskal-Wallis ANOVA	H (4) = 2.109	P = 0.2727
0 mins all conditions, FR	Figure 4	Kruskal-Wallis ANOVA	H (4) = 1.395	P = 0.8511
0 mins vs 32 mins, aSyn aggregates, IR	Figure 4	Wilcoxon signed-rank test	W(+) = 2.0, W(-) = 64.0, Z = 2.7	P = 0.0029
0 mins vs 32 mins, aSyn monomers, IR	Figure 4	Wilcoxon signed-rank test	W(+) = 6.5, W(-) = 14.5, Z = 0.73	P = 0.4688
0 mins vs 32 mins, vehicle, IR	Figure 4	Wilcoxon signed-rank test	W(+) = 46.0, W(-) = 9.0, Z = -1.83	P = 0.0645
32 mins, aSyn aggregates, aSyn monomers and vehicle, IR	Figure 4	Kruskal-Wallis ANOVA	H (2) = 14.53	P = 0.0007
16 mins, aSyn aggregates, aSyn monomers and vehicle, IR	Figure 4	Kruskal-Wallis ANOVA	H (2) = 10.67	P = 0.0048
0 mins vs 32 mins, vehicle, RMP	Figure 4	Wilcoxon signed-rank test	W(+) = 41.5, W(-) = 3.5, Z = -2.19	P = 0.0234
0 mins vs 32 mins, aSyn aggregates, RMP	Figure 4	Wilcoxon signed-rank test	W(+) = 61.0, W(-) = 5.0, Z = -2.44	P = 0.0107
0 mins vs 32 mins, aSyn monomers, RMP	Figure 4	Wilcoxon signed-rank test	W(+) = 19.5, W(-) = 1.5 Z = -1.79	P = 0.0938
32 mins, aSyn aggregates, aSyn monomers and vehicle, RMP	Figure 4	Kruskal-Wallis ANOVA	H (2) = 2.234	P = 0.3273
0 mins vs 32 mins, vehicle, FR	Figure 4	Wilcoxon signed-rank test	W(+) = 14, W(-) = 41.0 Z = -1.32	P = 0.1895
0 mins vs 32 mins, aSyn aggregates, FR	Figure 4	Wilcoxon signed-rank test	W(+) = 1.0, W(-) = 65.0 Z = 2.8	P = 0.0020
0 mins vs 32 mins, aSyn monomers, FR	Figure 4	Wilcoxon signed-rank test	W(+) = 11, W(-) = 10.0 Z = 0	P > 0.9999
32 mins, aSyn aggregates, aSyn monomers and vehicle, FR	Figure 4	Kruskal-Wallis ANOVA	H (2) = 10.21	P = 0.0061
0 mins, all conditions, capacitance	Figure 5	Kruskal-Wallis ANOVA	H (4) = 6.269	P = 0.18
0 mins vs 32 mins, aSyn aggregates, membrane conductance	Figure 5	Wilcoxon signed-rank test	W(+) = 66.0, W(-) = 0 Z = -2.89	P = 0.001
0 mins vs 32 mins, vehicle, membrane conductance	Figure 5	Wilcoxon signed-rank test	W(+) = 71.0, W(-) = 7 Z = -2.47	P = 0.009
32 mins, aSyn monomers and vehicle, membrane conductance	Figure 5	Mann-Whitney test	Vehicle median = 2.820, n=12, aSyn monomers = 2.820, n=6, U = 36	P > 0.9999
32 mins, aSyn aggregates and vehicle, membrane conductance	Figure 5	Mann-Whitney test	aSyn aggregates median = 6.450, n = 11,	P = 0.0003


			vehicle median = 2.820, n = 12, U = 11	
0 mins, vehicle and vehicle + glib, RMP	Figure 6	Mann-Whitney test	Vehicle median = -56, n = 10, Vehicle + Glib median = -54, n = 6, U = 21.50	P = 0.3791
0 mins, vehicle and vehicle + glib, IR	Figure 6	Mann-Whitney test	Vehicle median = 338.3, n = 10, Vehicle + Glib median = 393, n = 6, U = 18.50	P = 0.2294
0 mins, vehicle and vehicle + glib, FR	Figure 6	Mann-Whitney test	Vehicle median = 69.5, n = 10, Vehicle + Glib median = 86.5, n = 6, U = 25.50	P = 0.6548
0 mins vs 32 mins, vehicle + glib, IR	Figure 6	Wilcoxon signed-rank test	W(+) = 9.0, W(-) = 12.0 Z = 0.21	P = 0.8438
0 mins vs 32 mins, vehicle + glib, FR	Figure 6	Wilcoxon signed-rank test	W(+) = 7.0, W(-) = 14.0 Z = 0.63	P = 0.5625
0 mins vs 32 mins, aSyn + glib, IR	Figure 6	Wilcoxon signed-rank test	W(+) = 5.0, W(-) = 16.0 Z = 1.04	P = 0.25
0 mins vs 32 mins, aSyn + glib, FR	Figure 6	Wilcoxon signed-rank test	W(+) = 7.0, W(-) = 14.0 Z = 0.63	P = 0.353
0 mins vs 32 mins, aSyn + glib, membrane conductance	Figure 7	Wilcoxon signed-rank test	W(+) = 21.0, W(-) = 0 Z = 0.63	P = 0.0313
32 mins, vehicle + glib and aSyn + glib, membrane conductance	Figure 7	Mann-Whitney test	Vehicle + glib median = 4.675, n = 6, aSyn + glib median = 3.33, n = 6, U = 11	P = 0.3095
Normalised conductance over time, all conditions	Figure 7	Kruskal-Wallis ANOVA		
Conductance effect			F (4, 180) = 6.806	P < 0.0001
Time effect		Dunn's Posthoc analysis	F (4, 180) = 11.01	P < 0.0001
aSyn aggregates vs control				P < 0.0001
aSyn aggregates vs monomers				P = 0.0003
aSyn aggregates vs vehicle + glib				P < 0.0001
aSyn aggregates vs aSyn + Glib				P = 0.0045


889


890


Table 2: A table of all of the statistical tests and associated results.

















Table 1

Parameter	Vehicle/ control			aSyn aggregates			aSyn monomers			Glib + vehicle			Glib + aSyn aggregates		
	Mean	SEM	SD	Mean	SEM	SD	Mean	SEM	SD	Mean	SEM	SD	Mean	SEM	SD
RMP (mV)	-55.8	± 1.2	± 3.79	-55.4	± 1.23	± 4.10	-56.8	± 1.30	± 3.18	-53.2	± 2.14	± 5.24	-60.4	± 1.82	± 4.08
R in (MΩ)	338	± 17.6	± 55.8	312	± 17.1	± 56.8	359	± 42.2	± 103.3	386	± 25.2	± 61.7	294	± 41.9	± 93.6
Firing Rate (Hz)	1.63	± 0.39	± 0.12	2.51	± 1.57	± 0.47	2.38	± 1.14	± 0.46	2.27	± 1.15	± 0.47	2.04	± 1.29	± 0.52
C (pF)	88.8	± 5.74	± 14.1	107.8	± 5.84	± 14.3	80.73	± 15.1	± 37.0	81.16	± 8.54	± 20.9	117	± 22.3	± 54.7
g (nS)	2.29	± 0.2	± 0.49	2.78	± 0.2	± 0.49	1.99	± 0.3	± 0.73	2.39	± 0.29	± 0.71	3.67	± 0.55	± 1.35

Table 1: Electrophysiological parameters measured for dopaminergic neurons at time zero for all experimental treatments